Combination therapy for treating pulmonary hypertension
作者： Lawrence S. Zisman
DOI:
关键词:
摘要: The present disclosure describes a method of treating pulmonary disorders, such as arterial hypertension, using combination PDGF receptor kinase inhibitor, PDEV and an endothelin antagonist. compounds can inhibit cell growth proliferation target the underlying pathology PAH.
lens.org 参考文章(140)
Friedrich Grimminger, Ralph Theo Schermuly, PDGF receptor and its antagonists: role in treatment of PAH. Advances in Experimental Medicine and Biology. ,vol. 661, pp. 435- 446 ,(2010) , 10.1007/978-1-60761-500-2_28
Mark William Surber, Aerosol tyrosine kinase inhibitor compounds and uses thereof ,(2014)
Lee M. Greenberger, Xingzhi Tan, Frank Loganzo, Allan Wissner, Assays to identify irreversibly binding inhibitors of receptor tyrosine kinases ,(2005)
Thomas E. Tarara, Danforth Miller, Nagaraja Rao, Jeffry G. Weers, Daniel Huang, Dry powder formulations of particles that contain two or more active ingredients for treating obstructive or inflammatory airways diseases ,(2012)
Robert S. Schultz, Medically accurate pump system ,(2003)
Jerry March, Advanced Organic Chemistry: Reactions, Mechanisms, and Structure ,(1977)
Alfonso R. Gennaro, Remington: The Science and Practice of Pharmacy ,(2003)
Jon Adam Willardsen, Rachel Slade, Esther Arranz, Ashok C. Bajji, Eric DelMar, Jayasree M. Srinivasan, Compounds, compositions, and methods employing same ,(2005)
Donatella Chianelli, Valentina Molteni, Jon Loren, Juliet Nabakka, Xiaolin Li, Xiaodong Liu, 2-heteroarylamino-pyrimidine derivatives as kinase inhibitors ,(2008)